<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018261</url>
  </required_header>
  <id_info>
    <org_study_id>BST-LT-01</org_study_id>
    <nct_id>NCT04018261</nct_id>
  </id_info>
  <brief_title>Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients</brief_title>
  <official_title>A Prospective Multicenter Open-label, Not Controlled Phase Ib-II Clinical Trial to Assess the Safety and Immunologic Efficacy of Virus-specific T Lymphocytes From the Best Donor in Receptors of Hematopoietic Progenitor Allogeneic Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection&#xD;
      will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an&#xD;
      apheresis from a compatible donor.&#xD;
&#xD;
      Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days&#xD;
      after the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicentre, open-label and uncontrolled phase Ib-II clinical trial in which a&#xD;
      total of 20 patients ≥ 1 year of age with an allogeneic transplant of hematopoietic&#xD;
      progenitors and post-transplant CMV infection will be included. The main objective is to&#xD;
      evaluate the safety of the infusion of CMV activated T-lymphocytes and secondary objectives&#xD;
      are to evaluate the efficacy through clinical evolution, viral load, ability to induce&#xD;
      immunoreconstitution against the virus and evaluation of the persistence of specific T cells.&#xD;
&#xD;
      The treatment will be administered intravenously (central or peripheral route) in a single&#xD;
      dose at a dose of 0.01-5 E4 specific virus T lymphocytes per Kg of receptor weight. After the&#xD;
      infusion, patients will follow periodic controls (+7, +14, +21, +28, +45 and +60 days) in&#xD;
      which a clinical evaluation will be performed and blood samples will be obtained in order to&#xD;
      evaluate the persistence of specific T cells in the recipient:&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment: Adverse events</measure>
    <time_frame>60 days</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymerase chain reaction (PCR)</measure>
    <time_frame>+7, +14, +21, +28, +45, +60 days</time_frame>
    <description>Quantitative viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFN-γ+ spot forming cells</measure>
    <time_frame>+7, +14, +28, +60 days</time_frame>
    <description>Immune reconstitution by Elispot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte subpopulations</measure>
    <time_frame>+7, +14, +28, +60 days</time_frame>
    <description>Immune reconstitution by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell persistence by chimerism</measure>
    <time_frame>+14, +28 days</time_frame>
    <description>Detection of donor cellularity (administered product) in the receptor serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time elapsed in identifying the donor</measure>
    <time_frame>Day 0</time_frame>
    <description>Time elapsed between the patient's inclusion in the trial and confirmation of the donor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CMV Viremia</condition>
  <condition>Immunosuppression-related Infectious Disease</condition>
  <arm_group>
    <arm_group_label>Activated T-Lymphocytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Activated T-Lymphocytes</intervention_name>
    <description>Activated T-Lymphocytes will be infused intravenously in a single-dose</description>
    <arm_group_label>Activated T-Lymphocytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Recipient of an allogeneic hematopoietic progenitors cell transplant (irrespectively&#xD;
             of the donor source, donor type conditioning and underlying disease) that is beyond&#xD;
             the day +30 of the procedure&#xD;
&#xD;
          2. Patient with post-transplant infection due to CMV refractory or resistant to optimal&#xD;
             pharmacological treatment. Specifically, the patient must be included in any of the&#xD;
             following cases&#xD;
&#xD;
               1. Patient with organic disease caused by CMV (confirmed by histology) resistant to&#xD;
                  antiviral first line treatment&#xD;
&#xD;
               2. Patient with CMV reactivation and no organic disease, resistant or intolerant to&#xD;
                  2 previous antiviral treatment lines (ganciclovir/valganciclovir and foscarnet)&#xD;
                  or not candidate to be treated due to not acceptable expected toxicity (severe&#xD;
                  renal insufficiency, neutropenia or severe thrombopenia) It is agreed that the&#xD;
                  patient is affected with a resistant CMV infection if the CMV copies doesn't&#xD;
                  decrease in &gt; 1 log in total blood or otherwise the absolute number of copies &gt;&#xD;
                  1x10E4/mL in total blood after 2 weeks of antiviral treatment.&#xD;
&#xD;
               3. Patients with reactivation of recurrent CMV despite correct anti-CMV treatment.&#xD;
                  It will be considered a recurrent CMV infection if the patient has &gt; 2&#xD;
                  reactivations in a period &lt;6 months despite having received correct anti-CMV&#xD;
                  treatment&#xD;
&#xD;
               4. Documented genetic mutations associated with ganciclovir or foscarnet resistance&#xD;
&#xD;
          3. ≥ 1 year of age&#xD;
&#xD;
          4. Estimated life expectancy &gt; 30 days&#xD;
&#xD;
          5. Signature of the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute graft-versus-host disease (GVHD) ≥ grade II or chronic ≥ moderate&#xD;
&#xD;
          2. Corticosteroid ≥ 0.5mg/kg regardless the indication&#xD;
&#xD;
          3. Disease relapse at the time of infection or at any time after the Allogeneic&#xD;
             transplant.&#xD;
&#xD;
          4. Severe renal disease (creatinine &gt; 3gr/dL)&#xD;
&#xD;
          5. Severe hepatic disease (bilirubin &gt;3mg/dL or aspartate aminotransferase (AST) &gt;500&#xD;
             U/L) except if it is secondary to the viral infection.&#xD;
&#xD;
          6. Having received a donor lymphocytes infusion or any cell therapy product within 60&#xD;
             days prior to inclusion in the study (with the exception of transfusions), or having&#xD;
             it planned within the next 60 days.&#xD;
&#xD;
          7. Alteration of the general condition, infection or clinical or hemodynamic instability&#xD;
             that, in the opinion of the researcher, does not recommend the use of T cells&#xD;
&#xD;
          8. Known hypersensitivity to murine proteins or iron dextran.&#xD;
&#xD;
          9. Positive serology to human immunodeficiency virus (HIV), hepatitis B virus (HBV)&#xD;
             (HBsAg, HBcAc), hepatitis C virus (HCV) and/or syphilis&#xD;
&#xD;
         10. Pregnant, lactating or women without adequate contraception&#xD;
&#xD;
         11. Participation in a clinical trial with investigational medicinal products the last 30&#xD;
             days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Barba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VHIO (Vall d'Hebron Institute of Oncology)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Coll, MD</last_name>
    <phone>+34935573500</phone>
    <phone_ext>6707</phone_ext>
    <email>rucoll@bst.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Ferrá, MD, PhD</last_name>
      <phone>+34 934651200</phone>
      <email>cferra@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Christelle Ferrá, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Júlia Marsal, MD, PhD</last_name>
      <phone>+34 932532100</phone>
      <email>jmarsal@sjdhospitalbarcelona.org</email>
    </contact>
    <investigator>
      <last_name>Júlia Marsal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Izaskun Elorza Elorza, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO l'Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Parody, MD, PhD</last_name>
      <phone>+34 932607733</phone>
      <email>rparody@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Rocio Parody, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Martino, MD, PhD</last_name>
      <phone>+34 935565649</phone>
      <email>RMartino@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Rodrigo Martino, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Barba, MD, PhD</last_name>
      <phone>+34 934893000</phone>
      <email>pbarba@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Pere Barba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Alonso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Ortí, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Rovira, MD, PhD</last_name>
      <phone>+34 932275400</phone>
      <email>mrovira@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Montserrat Rovira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Montoro, MD</last_name>
      <phone>+34 961244000</phone>
      <email>juanmontorogomez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Montoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Guerreiro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net</url>
    <description>Blood and Tissue Bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.vhio.net</url>
    <description>Vall d'Hebron Institute of Oncology</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>Bone marrow transplant</keyword>
  <keyword>Activated T-Lymphocytes</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Virus infection</keyword>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

